



Trends in **Molecular Biology** • Special issue


Abstract Book

CoMBoS²

2nd Congress of Molecular Biologist of Serbia

Belgrade • 2023

ISBN-978-86-82679-15-8



**CoMBoS2 – the Second Congress of Molecular Biologists of Serbia,
Abstract Book – Trends in Molecular Biology, Special issue**

06-08 October 2023, Belgrade, Serbia

Online Edition

<https://www.imgge.bg.ac.rs/lat/o-nama/kapacitet-i-oprema/istrazivacka-delatnost>

<https://indico.bio.bg.ac.rs/e/CoMBoS2>

IMPRESSUM

PUBLISHER:

**Institute of Molecular Genetics and Genetic Engineering (IMGGE),
University of Belgrade**

FOR THE PUBLISHER:

Dr. Sonja **Pavlović**

EDITOR:

Dr. Zorana **Dobrijević**

EDITORIAL REVIEW BOARD:

Prof. Dr. Silvana **Andrić**

Dr. Valentina **Ćirković**

Dr. Ivica **Dimkić**

Prof. Dr. Branko **Jovčić**

Prof. Dr. Gordana **Matić**

Ass. Prof. Dr. Milena **Milutinović**

Dr. Aleksandra **Stanković**

Dr. Nemanja **Stanisavljević**

Dr. Maja **Stoiljković**

EDITOR IN CHIEF:

Prof. Dr. Dušanka **Savić-Pavićević**

DESIGN:

Ivan **Strahinić**

All rights reserved

Institute of Molecular Genetics and Genetic Engineering (IMGGE),

University of Belgrade

Belgrade, 2023

ISBN 978-86-7078-173-3

© Copyright 2023 by Institute of Molecular Genetics and Genetic Engineering (IMGGE), University of Belgrade
Belgrade • 2023

EPIGENETIC EDITING AS A POTENTIAL THERAPEUTIC TOOL FOR THE TREATMENT OF NONCOMMUNICABLE DISEASES

Aleksandra Uskoković¹

¹*Institute for Biological Research "Siniša Stanković", University of Belgrade, Belgrade, Serbia*

Epigenetic editing has a powerful potential to direct reprogramming of cellular phenotype that can be used in disease modeling. The reprogramming of cells from different origin into insulin-producing cells could provide a solution for restoring functional beta cell mass in diabetic patients. We used CRISPR/dCas9-based epigenetic tool for targeted hypermethylation of *Arx* promoter and its subsequent suppression in mouse pancreatic α cell line. By epigenetic silencing of *Arx* we successfully triggered a direct, transient switch of pancreatic α - to insulin-producing cells obtaining approximately 1% of transiently transfected cells which were able to produce 35% more insulin than Mock transfected α cells. As a future perspective we intend to address the potential use of epigenetic editing tool as a pre-therapeutic approach in triple-negative breast cancers (TNBCs) with unknown mutational signature of *BRCA1*. The *BRCA1* methylation (BRCAness) as a predictor for response to therapeutics such as PARPi would allow direct TNBC treatment without previous screening for *BRCA1* mutations. The main objective will be to induce BRCAness by suppressing *BRCA1* expression in TNBC cells via targeted DNA methylation of *BRCA1* promoter using the synthetic epigenetic editing tool. This approach would enable the faster decision toward the use of newest medicaments to increase cells' apoptosis and cancer cell diminishment.

Acknowledgements: This study was supported by the Ministry of Science, Technological Development and Innovation of the Republic of Serbia (451-03-47/2023-01/200007), EFSD and AvH programme.